• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Cullen Michael T.

    3/29/23 4:24:10 PM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBLA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Cullen Michael T.

    (Last) (First) (Middle)
    712 VISTA BLVD #305

    (Street)
    WACONIA MN 55387

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Panbela Therapeutics, Inc. [ PBLA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/27/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Rule 10b5-1(c) Transaction Indication

      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $0.5 03/27/2023 A 8,333 (1) 03/27/2033 Common Stock 8,333 $0 8,333 D
    Explanation of Responses:
    1. Options scheduled to vest on the earlier of day before annual meeting of stockholders or one year anniversary.
    /s/ Joshua L. Colburn, Attorney-in-Fact 03/29/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PBLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBLA

    DatePrice TargetRatingAnalyst
    6/28/2021$10.00Buy
    Roth Capital
    More analyst ratings

    $PBLA
    SEC Filings

    See more
    • Panbela Therapeutics Inc. filed SEC Form 8-K: Leadership Update

      8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)

      2/18/25 4:32:54 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)

      2/4/25 4:02:40 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela Therapeutics Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Changes in Control of Registrant

      8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)

      1/22/25 4:02:43 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Panbela Provides Business Update and Reports Q3 2024 Financial Results

      MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q3 2024 and Recent Highlights: Up to $12.0 million financing commitment secured from strategic investor, Nant Capital.First patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC). Jennifer K. Simpson,

      11/14/24 4:10:36 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

      MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call InformationToll Free: 877-545-0320International: 973-528-0002Participant Access Code: 370494Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/51548 Conference Call Replay InformationToll Free: 877-481-4010International: 919-882-2331Replay Passcode: 51548Webcast Replay: https://www.

      10/31/24 8:00:00 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center

      MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC). The initial goal of the Phase I trial will be to determine the maximum tolerated dose of eflornithine in combination with the immune checkpoint inhibitor Keytruda, while evaluating efficacy and then moving into a Phase II efficacy trial. Data from the Phase I trial is expected by mid-2025, with a look to start

      9/24/24 8:00:00 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Panbela Therapeutics Inc.

      SC 13D - Panbela Therapeutics, Inc. (0001029125) (Subject)

      10/29/24 7:40:55 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Panbela Therapeutics Inc. (Amendment)

      SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)

      2/13/24 8:10:27 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Panbela Therapeutics Inc. (Amendment)

      SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)

      2/14/23 2:45:11 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Nant Capital, Llc

      4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

      11/19/24 6:40:08 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Nant Capital, Llc

      3 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

      10/29/24 7:38:18 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by V.P. of Finance & CFO Horvath Susan

      4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

      10/3/24 4:26:59 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on Panbela Therapeutics with a new price target

      Roth Capital initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $10.00

      6/28/21 6:58:09 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Panbela Therapeutics with a new price target

      Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $8.00

      3/16/21 8:15:44 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Panbela Therapeutics with a new price target

      Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $8.00

      3/10/21 9:33:23 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBLA
    Financials

    Live finance-specific insights

    See more
    • Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

      MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call InformationToll Free: 877-545-0320International: 973-528-0002Participant Access Code: 370494Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/51548 Conference Call Replay InformationToll Free: 877-481-4010International: 919-882-2331Replay Passcode: 51548Webcast Replay: https://www.

      10/31/24 8:00:00 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024

      MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 405072Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50956 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50956Webcast Replay: https://www.webc

      7/30/24 4:15:00 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024

      MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024. Conference Call Information Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 234396Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50531 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50531Webcast Replay: https://www.webcas

      5/1/24 4:15:00 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care